Member Info for Reserved

The factsheet for the Act, which was referred to by Stefan, can be accessed via this website

https://ec.europa.eu/commission/presscorner/detail/en/fs_23_1663

I would be obliged if someone could explain the difference between the pilot at Pontefract Hospital and the YHEC evaluation.

Have the results of the Pontefract pilot been released?

1 Aug 2023 RNS

“Ondine commences first NHS Steriwave® pilot

Mid Yorkshire Teaching NHS Trust will be using Ondine's nasal photodisinfection therapy prior to orthopaedic surgeries at Pontefract Hospital over a six-month pilot”

5 Mar 2024 RNS

“Ondine starts first UK health economics study

The York Health Economic Consortium will undertake the first UK health economic analysis of Ondine's Steriwave light-activated antimicrobial to reduce Surgical Site Infections

Ondine Biomedical Inc. (LON:OBI), Mid Yorkshire Teaching NHS Trust, and Health Innovation Yorkshire and Humber are partnering with the York Health Economics Consortium (YHEC) to evaluate the use of Ondine's light-activated antimicrobial, Steriwave®, to reduce the incidence of surgical site infections (SSIs).”

Observation:

Since 11:21 yesterday the SP has reached 1.30 on 13 occasions before falling.

CrustyPete

I note your reference to risk identified by Liberum - "Further testing may suggest uncommercial status".

When considering risk, one needs to consider the probability that the event may occur. Each investor needs to review the information currently available and make their investment decision accordingly. A simplistic approach to this risk is to consider it in terms of Low / Medium / High.

The 2023 results should be available in May. Whilst more trials provide valuable information regarding the efficacy of the product and the potential cost savings, revenue generation is important. In 2022, there was loss before tax $19.5 million.

All the studies reported on so far show significant cost benefits, as well as better patient outcomes. I hope progress towards improving revenues has been made (2022 Revenues were $0.6 million)

I will be interested to see what progress has been made re the Phase 3 trial.

An article posted in the Jakata Times talks about the establishment of a cartel, similar to OPEC, for nickel producing countries:

"It may also be good to strengthen partnerships with other countries with major nickel reserves such as Australia, Brazil, Russia and New Caledonia, so that these producing countries can have better bargaining positions amid increasing demand for the mineral.

The idea to establish an OPEC-style organization for nickel was once introduced by President Joko “Jokowi” Widodo and Investment Minister Bahlil Lahadalia. Such an organization could help producing countries better coordinate supply and prices. Perhaps it is a good time to carry on with the plan."

The establishment of a cartel may never happen, but talk of one could increase the importance of an independent source in Europe, assuming Finland would not be interested in joining.

Link to full article: https://www.thejakartapost.com/opinion/2024/03/05/nickel-rush-needs-a-rethink.html

Tillerman

Thank you for an excellent post providing information about the cost of a trial.

Your reference to Ondine prompted me to review their Half Year Report (25/09/23); the report includes:

"FDA approval

We are continuing to work with FDA as well as our partner HCA Healthcare on the planning and execution of the pivotal Phase 3 study. Following a recent review meeting held with FDA on September 22, 2023, we can confirm that FDA has agreed that Ondine's summary of the extensive safety data is sufficient to proceed into the Phase 3. We are now working closely with FDA on specifics of the Phase 3 protocol."

QUESTION: Does working with their partner HCA Healthcare mean that the cost of the trial per patient could be significantly reduced?

An interesting article. The intervention of the Japanese government in 2010 to save the Australian miner Lynas Rare Earths by offering capital to completE mine development means there could be a range of financing options available to HZM.

On 01/08/23, Ondine issued an RNS stating

"Ondine commences first NHS Steriwave® pilot

Mid Yorkshire Teaching NHS Trust will be using Ondine's nasal photodisinfection therapy prior to orthopaedic surgeries at Pontefract Hospital over a six-month pilot"

Does anyone know if this was undertaken and, if so, when the results are likely to be published?

What, if any, are the implications for CMET?

The following paper:

https://www.boisestate.edu/earth/staff-members/dwanless1/dorsey-wanless-research/dwanless-research-projects/helium-hot-spring-gases-east-african-rift-system/

investigated the ratio of He3 to He4 and noted that the hot springs in Tanzania had better ratios than other hot springs associated with the rift valley in Africa. Since He3 is considerably rarer than He4, this raises the possibility that the helium from Itumbula will be more valuable than expected. It will be interesting to see if the lab results answer this question.

Thank you for providing clarification re Justin Waite's position.

As a newcomer and currently carrying a loss I was concerned to note that earlier threads refer to Justin Waite selling a large number of shares. Does that not seem strange if potential deals are likely to be imminent?

The New Scientist magazine, 03/02/24, had an interesting article on the formation of hydrogen. The article focusses on Oman where research is being undertaken to determine if they can create conditions that are capable of generating hydrogen.

Given the active geological conditions in the Rukwa Basin, hydrogen could be a very significant resource for HE1.

If several million $ are secured for Stanley, would Greenvale be necessary to progress matters if the Farm In agreement lapsed on 30/03/24?

Perhaps Nobles SP has not progressed after the 30% rise on 07/02/24 because there are too many qualifications in their announcement, e.g.

Cautionary Statement for Prospective Resource Estimates

With respect to the Prospective Resource estimates contained within this report, it should be noted that the

estimated quantities of gas that may potentially be recovered by the future application of a development project

relate to undiscovered accumulations. These estimates have an associated risk of discovery and risk of

development. Further exploration and appraisal is required to determine the existence of a significant quantity

of potentially moveable helium."

LB may want to be able to provide a greater degree of certainty before making announcements. I prefer to make decisions based on facts, rather than speculation.

FYI here is a link to a Noble announcement issued on 07/02/24.

https://www.investi.com.au/api/announcements/nhe/7c9f68d7-10a.pdf

I look forward to seeing a similar level of detail when our lab results arrive.

I am new to LSE, but have been following the discussion about XF-73 nasal and its significant benefits. Does anyone have information offering a comparison with Ondine's nasal photodisinfection.

I